10X GENOMICS ($TXG) posted quarterly earnings results for Q2 2026 on Thursday, August 6th. The company reported earnings of -$0.14 per share, beating estimates of -$0.25 by $0.11. The company also reported revenue of $151,040,000, beating estimates of $148,255,516 by $2,784,484.
Stock price change since market close: -3.93%
You can see Quiver Quantitative's $TXG stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
10X GENOMICS Insider Trading Activity
10X GENOMICS insiders have traded $TXG stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales.
Here’s a breakdown of recent trading of $TXG stock by insiders over the last 6 months:
- SERGE SAXONOV (Chief Executive Officer) has made 0 purchases and 12 sales selling 104,677 shares for an estimated $2,700,043.
- ADAM TAICH (Chief Financial Officer) has made 0 purchases and 2 sales selling 24,066 shares for an estimated $535,610.
- BENJAMIN J. HINDSON (See Remarks) has made 0 purchases and 2 sales selling 19,421 shares for an estimated $428,778.
- SHEHNAAZ SULIMAN has made 0 purchases and 2 sales selling 5,723 shares for an estimated $186,756.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
10X GENOMICS Hedge Fund Activity
We have seen 168 institutional investors add shares of 10X GENOMICS stock to their portfolio, and 139 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 5,823,490 shares (+48.9%) to their portfolio in Q1 2026, for an estimated $123,632,692
- WELLINGTON MANAGEMENT GROUP LLP removed 1,448,765 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $30,757,280
- BLUE WATER LIFE SCIENCE ADVISORS, LP added 1,090,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $23,140,700
- BALYASNY ASSET MANAGEMENT L.P. added 989,522 shares (+inf%) to their portfolio in Q1 2026, for an estimated $21,007,552
- SUMITOMO MITSUI TRUST GROUP, INC. removed 915,587 shares (-17.9%) from their portfolio in Q2 2026, for an estimated $35,103,605
- GOLDMAN SACHS GROUP INC added 884,533 shares (+28.7%) to their portfolio in Q1 2026, for an estimated $18,778,635
- CASDIN CAPITAL, LLC added 875,000 shares (+62.5%) to their portfolio in Q1 2026, for an estimated $18,576,250
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
10X GENOMICS Government Contracts
We have seen $6,006,700 of award payments to $TXG over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PROSTHETIST, PROSTHETIST TECHNICIAN, AND PROSTHETIST ASSISTANT IN THE DEPARTMENT OF SURGICAL SERVICES AND R...: $371,793
- GENE EXPRESSION REAGENTS: $334,142
- BIOLOGICAL REAGENT MATERIAL - CHROMIUM NEXT GEM SINGLE CELL MULTIOME AND GEM-X SINGLE CELL 5 KITS AND RELAT...: $249,991
- REAGENTS FOR ONGOING NGS PROJECTS (AMBIS 2270566): $249,963
- IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING - KITS AND REAGENTS USED IN SINGLE-CELL AND GENE PANEL ANALYSES: $249,934
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
10X GENOMICS Analyst Ratings
Wall Street analysts have issued reports on $TXG in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- William Blair issued a "Outperform" rating on 03/31/2026
To track analyst ratings and price targets for 10X GENOMICS, check out Quiver Quantitative's $TXG forecast page.
10X GENOMICS Price Targets
Multiple analysts have issued price targets for $TXG recently. We have seen 11 analysts offer price targets for $TXG in the last 6 months, with a median target of $32.0.
Here are some recent targets:
- Tejas Savant from Morgan Stanley set a target price of $37.0 on 07/09/2026
- Patrick Donnelly from Citigroup set a target price of $45.0 on 07/08/2026
- Eric Winmill from Scotiabank set a target price of $100.0 on 07/08/2026
- David Westenberg from Piper Sandler set a target price of $42.0 on 07/01/2026
- Luke Sergott from Barclays set a target price of $40.0 on 06/24/2026
- Casey Woodring from JP Morgan set a target price of $20.0 on 05/12/2026
- Kyle Mikson from Canaccord Genuity set a target price of $32.0 on 04/20/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
